Do analysts recommend NKTX or APLM?

Nkarta presently has a consensus target price of $11.20, suggesting a potential upside of 380.69%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts clearly believe Nkarta is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, NKTX or APLM?

Apollomics has higher revenue and earnings than Nkarta. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A Apollomics $8.50M 5.83 -$10.94M N/A N/A

Is NKTX or APLM more profitable?

Apollomics' return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -37.60% -29.25% Apollomics N/A N/A N/A

Does the media favor NKTX or APLM?

In the previous week, Nkarta had 15 more articles in the media than Apollomics. MarketBeat recorded 18 mentions for Nkarta and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.62 beat Nkarta's score of -0.14 indicating that Apollomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INDP or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, INDP or APLM?

Apollomics has higher revenue and earnings than Indaptus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A Apollomics $8.50M 5.83 -$10.94M N/A N/A

Is INDP or APLM more profitable?

Apollomics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Apollomics N/A N/A N/A

Does the media prefer INDP or APLM?

In the previous week, Indaptus Therapeutics had 4 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for Indaptus Therapeutics and 3 mentions for Apollomics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Apollomics' score of 0.62 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OTLK or APLM?

Oncobiologics currently has a consensus price target of $4.65, indicating a potential upside of 514.75%. Given Oncobiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, OTLK or APLM?

Apollomics has higher revenue and earnings than Oncobiologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncobiologics $1.35M 83.25 -$62.42M -$1.17 N/A Apollomics $8.50M 5.83 -$10.94M N/A N/A

Is OTLK or APLM more profitable?

Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Apollomics N/A N/A N/A

Does the media prefer OTLK or APLM?

In the previous week, Oncobiologics had 8 more articles in the media than Apollomics. MarketBeat recorded 11 mentions for Oncobiologics and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.62 beat Oncobiologics' score of 0.37 indicating that Apollomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate APLM or EQ?

Equillium has a consensus target price of $7.57, indicating a potential upside of 220.82%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Equillium 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91

Which has preferable earnings & valuation, APLM or EQ?

Apollomics has higher earnings, but lower revenue than Equillium. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.83 -$10.94M N/A N/A Equillium $41.10M 3.63 -$22.40M -$0.32 N/A

Is APLM or EQ more profitable?

Apollomics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Equillium N/A -61.43% -53.72%

Does the media favor APLM or EQ?

In the previous week, Equillium had 4 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for Equillium and 3 mentions for Apollomics. Equillium's average media sentiment score of 1.56 beat Apollomics' score of 0.62 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate ADCT or APLM?

ADC Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 521.89%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe ADC Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ADCT or APLM?

Apollomics has lower revenue, but higher earnings than ADC Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADC Therapeutics $81.36M 1.57 -$142.62M -$1.05 N/A Apollomics $8.50M 5.83 -$10.94M N/A N/A

Is ADCT or APLM more profitable?

Apollomics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics -173.02% N/A -44.70% Apollomics N/A N/A N/A

Does the media prefer ADCT or APLM?

In the previous week, ADC Therapeutics had 4 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for ADC Therapeutics and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.56 indicating that Apollomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Apollomics (APLM) Competitors

$22.54 +5.17 (+29.75%)

Closing price 03:58 PM Eastern

Extended Trading

$21.86 -0.68 (-3.01%)

As of 07:34 PM Eastern

Compare

APLM vs. NKTX, INDP, OTLK, EQ, and ADCT

Should you buy Apollomics stock or one of its competitors? Apollomics's main competitors and comparable companies include Nkarta (NKTX), Indaptus Therapeutics (INDP), Oncobiologics (OTLK), Equillium (EQ), and ADC Therapeutics (ADCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Apollomics compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

In the previous week, Nkarta had 15 more articles in the media than Apollomics. MarketBeat recorded 18 mentions for Nkarta and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.62 beat Nkarta's score of -0.14 indicating that Apollomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nkarta presently has a consensus target price of $11.20, suggesting a potential upside of 380.69%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts clearly believe Nkarta is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has higher revenue and earnings than Nkarta.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Apollomics	$8.50M	5.83	-$10.94M	N/A	N/A

80.5% of Nkarta shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Apollomics' return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-37.60%	-29.25%
Apollomics	N/A	N/A	N/A

Nkarta has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Summary

Nkarta beats Apollomics on 7 of the 13 factors compared between the two stocks.

How does Apollomics compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Apollomics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Apollomics	N/A	N/A	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Apollomics has higher revenue and earnings than Indaptus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Apollomics	$8.50M	5.83	-$10.94M	N/A	N/A

In the previous week, Indaptus Therapeutics had 4 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for Indaptus Therapeutics and 3 mentions for Apollomics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Apollomics' score of 0.62 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Summary

Apollomics beats Indaptus Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Apollomics compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Oncobiologics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Apollomics has higher revenue and earnings than Oncobiologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	83.25	-$62.42M	-$1.17	N/A
Apollomics	$8.50M	5.83	-$10.94M	N/A	N/A

In the previous week, Oncobiologics had 8 more articles in the media than Apollomics. MarketBeat recorded 11 mentions for Oncobiologics and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.62 beat Oncobiologics' score of 0.37 indicating that Apollomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics currently has a consensus price target of $4.65, indicating a potential upside of 514.75%. Given Oncobiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Apollomics	N/A	N/A	N/A

Summary

Oncobiologics and Apollomics tied by winning 6 of the 12 factors compared between the two stocks.

How does Apollomics compare to Equillium?

Apollomics (NASDAQ:APLM) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Apollomics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Equillium	N/A	-61.43%	-53.72%

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Apollomics has higher earnings, but lower revenue than Equillium.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.83	-$10.94M	N/A	N/A
Equillium	$41.10M	3.63	-$22.40M	-$0.32	N/A

In the previous week, Equillium had 4 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for Equillium and 3 mentions for Apollomics. Equillium's average media sentiment score of 1.56 beat Apollomics' score of 0.62 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Equillium has a consensus target price of $7.57, indicating a potential upside of 220.82%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Apollomics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Equillium has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market.

Summary

Equillium beats Apollomics on 10 of the 14 factors compared between the two stocks.

How does Apollomics compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Apollomics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Apollomics	N/A	N/A	N/A

ADC Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 521.89%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe ADC Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ADC Therapeutics had 4 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for ADC Therapeutics and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.56 indicating that Apollomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADC Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Apollomics has lower revenue, but higher earnings than ADC Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.57	-$142.62M	-$1.05	N/A
Apollomics	$8.50M	5.83	-$10.94M	N/A	N/A

Summary

ADC Therapeutics beats Apollomics on 8 of the 13 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$49.58M	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	N/A	10.68	269.86	25.30
Price / Sales	5.83	1,308.25	601.81	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	-7.80	17.49	13.08	6.33
Net Income	-$10.94M	-$13.32M	$3.45B	$347.70M
7 Day Performance	28.06%	1.74%	1.12%	1.07%
1 Month Performance	43.55%	1.60%	1.79%	1.03%
1 Year Performance	281.03%	56.43%	67.69%	20.77%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	1.316 of 5 stars	$22.54 +29.8%	N/A	+208.0%	$38.15M	$8.50M	N/A	45	Gap Up
NKTX Nkarta	3.0901 of 5 stars	$2.23 -1.5%	$10.75 +383.1%	+4.1%	$158.46M	N/A	N/A	140	Trending News Earnings Report Analyst Forecast Analyst Revision
INDP Indaptus Therapeutics	1.3073 of 5 stars	$1.39 +2.5%	N/A	-87.4%	$157.52M	N/A	N/A	6	News Coverage Positive News Earnings Report Upcoming Earnings Short Interest Decrease Gap Up
OTLK Oncobiologics	3.587 of 5 stars	$1.03 +6.7%	$4.65 +353.7%	-58.3%	$152.31M	$1.35M	N/A	20	News Coverage Earnings Report Analyst Upgrade Short Interest Increase Gap Down
EQ Equillium	3.0365 of 5 stars	$2.27 +0.2%	$7.57 +234.3%	+116.1%	$142.90M	$41.10M	N/A	40	News Coverage Positive News Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. NKTX, INDP, OTLK, EQ, and ADCT

How does Apollomics compare to Nkarta?

Summary

How does Apollomics compare to Indaptus Therapeutics?

Summary

How does Apollomics compare to Oncobiologics?

Summary

How does Apollomics compare to Equillium?

Summary

How does Apollomics compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. NKTX, INDP, OTLK, EQ, and ADCT

How does Apollomics compare to Nkarta?

Does the media favor NKTX or APLM?

Do analysts recommend NKTX or APLM?

Which has higher earnings & valuation, NKTX or APLM?

Do institutionals and insiders hold more shares of NKTX or APLM?

Is NKTX or APLM more profitable?

Which has more volatility and risk, NKTX or APLM?

Summary

How does Apollomics compare to Indaptus Therapeutics?

Is INDP or APLM more profitable?

Do institutionals and insiders have more ownership in INDP or APLM?

Which has higher valuation & earnings, INDP or APLM?

Does the media prefer INDP or APLM?

Do analysts prefer INDP or APLM?

Which has more risk and volatility, INDP or APLM?

Summary

How does Apollomics compare to Oncobiologics?

Which has more risk & volatility, OTLK or APLM?

Which has better earnings and valuation, OTLK or APLM?

Does the media prefer OTLK or APLM?

Do analysts recommend OTLK or APLM?

Do insiders and institutionals have more ownership in OTLK or APLM?

Is OTLK or APLM more profitable?

Summary

How does Apollomics compare to Equillium?

Is APLM or EQ more profitable?

Do insiders & institutionals believe in APLM or EQ?

Which has preferable earnings & valuation, APLM or EQ?

Does the media favor APLM or EQ?

Do analysts rate APLM or EQ?

Which has more risk & volatility, APLM or EQ?

Summary

How does Apollomics compare to ADC Therapeutics?

Do insiders and institutionals hold more shares of ADCT or APLM?

Is ADCT or APLM more profitable?

Do analysts rate ADCT or APLM?

Does the media prefer ADCT or APLM?

Which has more risk and volatility, ADCT or APLM?

Which has preferable valuation & earnings, ADCT or APLM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools